GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genpharmasec Ltd (BOM:531592) » Definitions » Net-Net Working Capital

Genpharmasec (BOM:531592) Net-Net Working Capital : ₹0.09 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Genpharmasec Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Genpharmasec's Net-Net Working Capital for the quarter that ended in Mar. 2025 was ₹0.09.

The industry rank for Genpharmasec's Net-Net Working Capital or its related term are showing as below:

BOM:531592's Price-to-Net-Net-Working-Capital is ranked worse than
86.53% of 401 companies
in the Drug Manufacturers industry
Industry Median: 7.7 vs BOM:531592: 23.67

Genpharmasec Net-Net Working Capital Historical Data

The historical data trend for Genpharmasec's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genpharmasec Net-Net Working Capital Chart

Genpharmasec Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.16 0.16 0.45 0.09

Genpharmasec Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 - 0.06 - 0.09

Competitive Comparison of Genpharmasec's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Genpharmasec's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genpharmasec's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genpharmasec's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Genpharmasec's Price-to-Net-Net-Working-Capital falls into.


;
;

Genpharmasec Net-Net Working Capital Calculation

Genpharmasec's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Mar. 2025 is calculated as

Net-Net Working Capital(A: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(52.714+0.75 * 135.963+0.5 * 81.977-146.126
-0-1.165)/553.720
=0.09

Genpharmasec's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2025 is calculated as

Net-Net Working Capital(Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(52.714+0.75 * 135.963+0.5 * 81.977-146.126
-0-1.165)/553.720
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Genpharmasec  (BOM:531592) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Genpharmasec Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Genpharmasec's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Genpharmasec Business Description

Traded in Other Exchanges
N/A
Address
Akurli Road, Office No. 104 and 105, 1st Floor, Gundecha Industrial Premises Co-op Soc. Ltd., Kandivali (East), Mumbai, MH, IND, 400101
Genpharmasec Ltd is engaged in pharmaceutical activities and services. The company operates in two reportable segments namely; Diagnostic Pharma Equipment which includes pharmaceutical, medicinal, and medicated preparations, patent medicines, drugs, and herbs, and pharmaceutical, medicinal, and proprietary and industrial preparations, compounds, and articles of kinds, chemists, druggists, and chemical manufacturers. The Trading in the Securities segment of the company invests in the secondary securities market. The Diagnostic Pharma Equipment segment is the key revenue generator for the group.

Genpharmasec Headlines

No Headlines